Sponsored by Cytiva
Filtration of protein-based biologics is essential for minimizing viral contamination and ensuring product safety and high quality. The tendency of therapeutic monoclonal antibodies (MAbs) and recombinant proteins to aggregate under a number of conditions can complicate selection of a virus filter. An increasing demand for high concentration formulations creates additional challenges. When performing filterability studies and to ensure meaningful virus filter evaluations, downstream process scientists must address factors that can lead to aggregation.
This special report on virus filtration by scientists at Pall includes discussion of minimizing protein aggregation through formulation and handling considerations. Download now to learn more.
You May Also Like
